Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Abatacept in Anti-synthetase Syndrome-associated ILD
NCT03215927Phase 2Completed
- Start
- Jan 2018
- Primary completion
- May 2022
- Modality
- Fc-Fusion Proteins
- Countries
- 1
01
Overview
A Phase 2 trial of abatacept in interstitial lung disease (ILD). Started Jan 2018; status: completed.
02
Drugs
abatacept
03
Conditions
interstitial lung disease (ILD)
Beyond the preview
Go deeper on NCT03215927.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03215927.